CRX Cyprotex

TIDMCRX

RNS Number : 2148N

Cyprotex PLC

21 October 2016

Cyprotex PLC

("Cyprotex" or "the Company")

Director Declaration

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, today announces that in accordance with AIM Rule 17 of the AIM Rules for Companies, it has been informed, that on 19 October 2016, Mr Ian Johnson, the Chairman of Cyprotex, and Mr Christopher Mills, a Non-Executive Director of Cyprotex, were both appointed as Non-Executive Directors of Quantum Pharma plc.

For further information:

 
 Cyprotex PLC                         Tel: +44 (0) 1625 
                                       505 100 
 Dr Anthony Baxter, Chief Executive   ir@cyprotex.com 
  Officer                              www.cyprotex.com 
  John Dootson, Chief Financial 
  Officer 
  Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 
 N+1 Singer (Nomad & Broker)          Tel: +44 (0)20 7496 
                                       3000 
 Shaun Dobson                         shaun.dobson@n1singer.com 
  Jen Boorer                           jennifer.boorer@n1singer.com 
                                       www.n1singer.com 
 

Notes to Editors

About Cyprotex PLC

Cyprotex is quoted on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe(R) PK, chemPK(TM) and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDNAKDDBQBDDFKB

(END) Dow Jones Newswires

October 21, 2016 10:31 ET (14:31 GMT)

Cyprotex (LSE:CRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024

Cyprotex (LSE:CRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024